Pitcairn’s Core Laboratories CLB Stock Holding History

Pitcairn’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,931	Closed	-$1.32M	–	489
2014 Q4	$1.32M	Sell	10,931 -410	-4%	-$53.9K	0.14%	124
2014 Q3	$1.66M	Sell	11,341 -349	-3%	-$53.9K	0.19%	101
2014 Q2	$1.95M	Buy	11,690 +2,452	+27%	+$436K	0.22%	85
2014 Q1	$1.83M	Buy	+9,238	New	+$1.74M	0.2%	89

Other funds holding CLB

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return

Pitcairn's CLB Position: Q1 2015 in Review

Pitcairn sold out of Core Laboratories (CLB) in Q1 2015, closing a stake of 10,931 shares — an estimated $1.32M sold.

Pitcairn first reported a position in CLB in Q1 2014 and held it in 4 quarters. The position peaked at $1.95M in Q2 2014. 347 funds tracked by Wall St. Rank hold CLB as of Q1 2015.

Pitcairn reported no remaining Core Laboratories position as of Q1 2015 after selling out during the quarter.
Pitcairn sold 10,931 Core Laboratories shares in Q1 2015, an estimated $1.32M.
Pitcairn first reported a position in Core Laboratories in Q1 2014 and held it in 4 quarters.
Pitcairn's Core Laboratories position peaked at $1.95M in Q2 2014.
347 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2015.

Based on Pitcairn's 13F filing for Q1 2015, filed 14 May 2015.